Coupon
Mhc Class I Antigens in Malignant Cells : Immune Escape and Response to Immunotherapy
by Natalia Aptsiauri and Angel Miguel Garcia-Lora and Teresa Cabrera


Overview - Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches.  Read more...

 
Paperback
  • $69.99

Add to Cart + Add to Wishlist

In Stock

Free Shipping is not available for this item.
 
> Check In-Store Availability

In-Store pricing may vary

 
 
New & Used Marketplace 10 copies from $22.53
 
 
 

More About Mhc Class I Antigens in Malignant Cells by Natalia Aptsiauri; Angel Miguel Garcia-Lora; Teresa Cabrera
 
 
 
Overview
Abnormal expression of MHC class I molecules in malignant cells is a frequent occurrence that ranges from total loss of all class I antigens to partial loss of MHC specific haplotypes or alleles. Different mechanisms are described to be responsible for these alterations, requiring different therapeutic approaches. A complete characterization of these molecular defects is important for improvement of the strategies for the selection and follow-up of patients undergoing T-cell based cancer immunotherapy. Precise identification of the mechanism leading to MHC class I defects will help to develop new personalized patient-tailored treatment protocols. There is significant new research on the prevalence of various patterns of MHC class I defects and the underlying molecular mechanisms in different types of cancer. In contrast, few data is available on the changes in MHC class I expression during the course of cancer immunotherapy, but the authors have recently made discoveries that show the progression or regression of a tumor lesion in cancer patients undergoing immunotherapy depends on the molecular mechanism responsible for the MHC class I alteration and not on the type of immunotherapy used. According to this notion, the nature of the preexisting MHC class I lesion in the cancer cell has a crucial impact on determining the final outcome of cancer immunotherapy. This SpringerBrief will present how MHC class 1 is expressed, explain its role in tumor progression, and its role in resistance to immunotherapy. ​

 
Details
  • ISBN-13: 9781461465423
  • ISBN-10: 1461465427
  • Publisher: Springer
  • Publish Date: February 2013
  • Page Count: 51
  • Dimensions: 8.9 x 5.9 x 0.3 inches
  • Shipping Weight: 0.4 pounds

Series: Springerbriefs in Cancer Research #6

Related Categories

Books > Medical > Immunology
Books > Science > Life Sciences - Molecular Biology
Books > Medical > Oncology

 
BAM Customer Reviews